Changing a component in a validated biopharmaceutical process is rarely as simple as replacing one product with another. Even when two bottles appear comparable, quality, regulatory, and engineering teams may need to evaluate the material of construction, dimensions, closure interface, sterilization method, extractables profile, functional performance, and potential effect on the process.
The objective is not to avoid change control or validation. It is to determine which qualification activities are scientifically justified for the specific change.
Not All Change Is Equal
Pharmaceutical quality guidance supports a risk-based approach to manufacturing changes.
ICH Q10 calls for proposed changes to be evaluated by personnel with appropriate expertise from areas such as development, manufacturing, quality, and regulatory affairs. The change should be technically justified, evaluated against predetermined criteria, and reviewed after implementation to confirm that it did not negatively affect product quality.[1]
ICH Q9 further establishes that the level of effort, formality, and documentation applied to a quality-risk assessment should be appropriate to the level of risk.[2]
For a PETG bottle change, this means the assessment should focus on the characteristics that could realistically affect the process or product, not simply assume that every part of the manufacturing process must be repeated.
What Makes a Bottle Comparable
A replacement is easier to assess when it closely aligns with the component already in use. Relevant areas of comparison may include:
- Resin identity and formulation
- Bottle nominal value
- Closure and port compatibility
- Surface area and product-contact configuration
- Operating temperature and storage conditions
- Sterilization method and dose range
- Mechanical and functional performance
- Extractables and chemical-characterization data
- Particulate, endotoxin, and cleanliness specifications
- Supplier quality and change-notification practices
The phrase “same PETG resin” is valuable, but it should not stand alone. Resin identity is one part of comparability. Manufacturing conditions, additives, irradiation, component geometry, and contact conditions can also influence the performance and extractables profile of a plastic process component.
Why Extractables Data Matter
Plastic components used during biopharmaceutical manufacturing can release chemical compounds into process fluids under certain conditions. If those compounds persist through the manufacturing process, they may become process equipment-related leachables.
Published research has shown that plastic tubing, storage containers, filters, gaskets, and other process-contact components can represent potential sources of these compounds. The actual risk depends on factors such as contact time, temperature, solvent characteristics, surface-area-to-volume ratio, position in the process, and the ability of downstream operations to remove or dilute the compounds.[3–5]
This is why standardized extractables data can make a supplier change more manageable: the data give quality and regulatory teams a scientific basis for determining whether additional application-specific studies are needed.
USP <665> addresses plastic components and systems used to manufacture pharmaceutical drug products and biopharmaceutical drug substances and products. Its companion chapter, USP <1665>, provides a framework for characterization and qualification.[6,7]
These chapters do not eliminate the manufacturer’s responsibility to assess the change. They help organize the evidence needed to make that assessment.
A bottle change should never be treated as a simple purchasing substitution.
Narrowing the Validation Question
A well-supported replacement package may allow the change-control team to move from a broad question, “Do we need to revalidate the process?”, to a more focused set of questions:
- Is the material of construction equivalent or sufficiently comparable?
- Will the bottle fit the existing equipment and fluid path?
- Are process-contact conditions within the supplier’s tested range?
- Does the extractables profile present any new or increased risk?
- Does sterilization affect the component differently?
- Are additional engineering, functional, or product-specific studies necessary?
- Could the change affect a registered condition or regulatory filing?
Depending on the application, the resulting work might include a document review, functional verification, an engineering run, a targeted extractables or leachables assessment, product-contact testing, or selected process confirmation. The scope should be established by the manufacturer’s own quality system and risk assessment.
How SaniSure Supports the Switch
SaniSure PharmaTainer™ bottles are manufactured using Eastman Eastar™ 6763 PETG resin and are designed to provide a familiar bottle format and functionality for biopharmaceutical processing applications.
To support customer evaluation, SaniSure can provide:
- Material and resin information
- Dimensional and functional specifications
- Validation documentation under a nondisclosure agreement
- Available extractables and USP <665> testing
- Cleanliness and quality documentation
- Technical support for change-control discussions
This information does not replace a customer’s validation or quality procedures. It can, however, provide the evidence needed to conduct a more focused and predictable assessment. When the replacement is technically comparable and supported by relevant documentation, the path forward may not require revalidating more of the process than the risk justifies.